902837-62-1

Usage

Uses

Used in Pharmaceutical Industry:
1-Ethyl-1H-pyrazole-5-carboxaldehyde is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs, enhancing the range of therapeutic options available.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 1-Ethyl-1H-pyrazole-5-carboxaldehyde serves as an intermediate in the production of pesticides. Its role in creating effective and novel agrochemicals is vital for improving crop protection and management strategies.
Used in Organic Compounds Synthesis:
Beyond its applications in药品 and agrochemicals, 1-Ethyl-1H-pyrazole-5-carboxaldehyde is also utilized in the synthesis of other organic compounds. Its versatility in chemical reactions makes it a valuable asset in the creation of a diverse array of organic products.

InChI:InChI=1S/C6H8N2O/c1-2-8-6(5-9)3-4-7-8/h3-5H,2H2,1H3

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 2817-71-2 1-ethyl-1H-pyrazole 

Downstream Products

• 1007488-29-0 (1-ethyl-1H-pyrazol-5-yl)methanol 
• 1428968-91-5 2-(1-ethyl-1H-pyrazol-5-yl)-1-(1H-indol-3-yl)-2-((3-methoxyphenyl)amino)ethanone 
• 1428972-62-6 N-((1-ethyl-1H-pyrazol-5-yl)methylene)-3-methoxyaniline 

Relevant academic research and scientific papers

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Myeloid cell leukemia 1 (Mcl-1) has emerged as an attractive target for cancer therapy. It is an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. Here we report the discovery of our clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. Starting from a fragment derived lead compound, we have conducted structure guided optimization that has led to a significant (3 log) improvement of target affinity as well as cellular potency. The presence of hindered rotation along a biaryl axis has conferred high selectivity to the compounds against other members of the Bcl-2 family. During optimization, we have also established predictive PD markers of Mcl-1 inhibition and achieved both efficient in vitro cell killing and tumor regression in Mcl-1 dependent cancer models. The preclinical candidate has drug-like properties that have enabled its development and entry into clinical trials.

NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

Spin transition in the molecular heterospin complex of Cu(hfac)2 with 4,4,5,5-tetramethyl-2-(1-methylpyrazol-5-yl)-4,5-dihydroimidazole-1-oxyl 3-oxide

The synthesis, structure, and magnetic properties of the products of the reaction for Cu(hfac)2 (hfac is hexafluoroacetylacetonate) with spin-labeled nitronyl nitroxides 4,4,5,5-tetramethyl-2-(1-R-1H-pyrazol-5-yl)-3- imidazoline-1-oxyl 3-oxides L5/R (R = Me, Et, Pr, Bu), viz., binuclear complex [Cu(hfac)2L5/Me]2 and chain polymer complexes [Cu(hfac)2L5/R]n, are described. The polymer heterospin chains are built according to head-to-head (R = Me, Et, Pr, Bu) and head-to-tail (R = Pr, Bu) motifs. Compound [Cu(hfac)2L5/Me]2 is characterized by the ability to reveal the reversible effect of thermally induced spin transition at a temperature about 75 K (without hysteresis). In the set of heterospin CuII compounds with spin-labeled pyrazoles, this is the earlier unknown example of a molecular complex exhibiting a similar magnetic anomaly.